Graviton Bioscience
Emmanuelle Zaoui is currently the Vice President of AI & Operations at a cutting-edge biotech company focused on autoimmune, fibrotic & CNS diseases. Prior to this role, Emmanuelle worked at Geneva Technologies, spearheading online communications for groups & communities. Emmanuelle holds an MBA from Columbia Business School and a BA in Politics, Philosophy & Economics from the University of Pennsylvania.
Graviton Bioscience
Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2), along with other therapeutic compounds.